PT1835922E - Tratamento combinado para esclerose múltipla - Google Patents
Tratamento combinado para esclerose múltipla Download PDFInfo
- Publication number
- PT1835922E PT1835922E PT05823965T PT05823965T PT1835922E PT 1835922 E PT1835922 E PT 1835922E PT 05823965 T PT05823965 T PT 05823965T PT 05823965 T PT05823965 T PT 05823965T PT 1835922 E PT1835922 E PT 1835922E
- Authority
- PT
- Portugal
- Prior art keywords
- multiple sclerosis
- combination treatment
- cda
- alpha
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transplanting Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63867404P | 2004-12-22 | 2004-12-22 | |
| EP04106910 | 2004-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1835922E true PT1835922E (pt) | 2009-07-08 |
Family
ID=35789196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05823965T PT1835922E (pt) | 2004-12-22 | 2005-12-20 | Tratamento combinado para esclerose múltipla |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100129353A1 (pt) |
| EP (1) | EP1835922B1 (pt) |
| JP (1) | JP2008524310A (pt) |
| AT (1) | ATE431740T1 (pt) |
| AU (1) | AU2005318183B2 (pt) |
| CA (1) | CA2590471A1 (pt) |
| CY (1) | CY1109316T1 (pt) |
| DE (1) | DE602005014570D1 (pt) |
| DK (1) | DK1835922T3 (pt) |
| ES (1) | ES2325552T3 (pt) |
| HR (1) | HRP20090417T1 (pt) |
| IL (1) | IL183924A (pt) |
| NO (1) | NO20073635L (pt) |
| PL (1) | PL1835922T3 (pt) |
| PT (1) | PT1835922E (pt) |
| SI (1) | SI1835922T1 (pt) |
| WO (1) | WO2006067134A1 (pt) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) * | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) * | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011236A1 (en) * | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5208327A (en) * | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| AR038605A1 (es) * | 2002-02-25 | 2005-01-19 | Elan Pharm Inc | Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento |
| EA009714B1 (ru) * | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
-
2005
- 2005-12-20 PT PT05823965T patent/PT1835922E/pt unknown
- 2005-12-20 DK DK05823965T patent/DK1835922T3/da active
- 2005-12-20 AU AU2005318183A patent/AU2005318183B2/en not_active Ceased
- 2005-12-20 EP EP05823965A patent/EP1835922B1/en active Active
- 2005-12-20 DE DE602005014570T patent/DE602005014570D1/de active Active
- 2005-12-20 CA CA002590471A patent/CA2590471A1/en not_active Abandoned
- 2005-12-20 PL PL05823965T patent/PL1835922T3/pl unknown
- 2005-12-20 WO PCT/EP2005/056943 patent/WO2006067134A1/en active Application Filing
- 2005-12-20 JP JP2007547483A patent/JP2008524310A/ja not_active Withdrawn
- 2005-12-20 SI SI200530731T patent/SI1835922T1/sl unknown
- 2005-12-20 AT AT05823965T patent/ATE431740T1/de active
- 2005-12-20 US US11/722,487 patent/US20100129353A1/en not_active Abandoned
- 2005-12-20 ES ES05823965T patent/ES2325552T3/es active Active
-
2007
- 2007-06-14 IL IL183924A patent/IL183924A/en not_active IP Right Cessation
- 2007-07-13 NO NO20073635A patent/NO20073635L/no not_active Application Discontinuation
-
2009
- 2009-07-27 HR HR20090417T patent/HRP20090417T1/xx unknown
- 2009-08-12 CY CY20091100869T patent/CY1109316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2325552T3 (es) | 2009-09-08 |
| CA2590471A1 (en) | 2006-06-29 |
| DK1835922T3 (da) | 2009-08-03 |
| CY1109316T1 (el) | 2014-07-02 |
| NO20073635L (no) | 2007-09-24 |
| IL183924A0 (en) | 2007-10-31 |
| ATE431740T1 (de) | 2009-06-15 |
| JP2008524310A (ja) | 2008-07-10 |
| WO2006067134A1 (en) | 2006-06-29 |
| IL183924A (en) | 2010-11-30 |
| HRP20090417T1 (en) | 2009-09-30 |
| AU2005318183B2 (en) | 2011-03-31 |
| PL1835922T3 (pl) | 2009-10-30 |
| US20100129353A1 (en) | 2010-05-27 |
| DE602005014570D1 (pt) | 2009-07-02 |
| EP1835922A1 (en) | 2007-09-26 |
| SI1835922T1 (sl) | 2009-10-31 |
| AU2005318183A1 (en) | 2006-06-29 |
| EP1835922B1 (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| EP3530288A3 (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
| NO20052362L (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| HUP0002755A2 (hu) | Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal | |
| SG160323A1 (en) | Methods for controlling angiogenesis and cell proliferation | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| DK1140198T3 (da) | Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad | |
| WO2003049694A3 (en) | Methods of therapy for non-hodgkin's lymphoma | |
| HK1112721A1 (en) | Tissue disruption treatment and composition for use thereof | |
| WO2005009363A3 (en) | Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| JP2003528919A5 (pt) | ||
| HK1045456A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| DE602005014570D1 (pt) | ||
| TW200628162A (en) | Combination treatment for multiple sclerosis | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| WO2003103675A3 (en) | COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| EP1374873B8 (en) | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |